ArticleBritish journal of cancer2020

Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.

Divya Subramonian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.